SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tktom who wrote (4116)2/2/2016 12:54:31 PM
From: Biomaven  Respond to of 4474
 
>>'788 is targeting two mutations, EGFR and HER2, driven by exon 20 insertion mutations, doesn't that reduce the chances of early approval after a phase 2

Can't tell much until we see the preclinical data.

For '113, there was a significant difference in potency between ALK and EGFR - something I pointed out as soon as they disclosed it.

Resistant EGFR is a tougher target clinically than ALK,. likely because there are multiple modes of resistance.

nature.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News